Drug delivery and formulations for the topical treatment of psoriasis
- 5 February 2008
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Drug Delivery
- Vol. 5 (2), 235-249
- https://doi.org/10.1517/17425247.5.2.235
Abstract
Background: Psoriasis is one of the most common human skin diseases. It is characterised by excessive growth and aberrant differentiation of corneocytes, but is fully reversible with appropriate therapy. Objective: There are many drug therapies for psoriasis via the topical delivery route. This review describes the topically applied drugs used to treat psoriasis. Methods: Formulations to carry or encapsulate these drugs are introduced in this review. Enhancing approaches such as liposome inclusion, iontophoresis and laser are also discussed. Conclusion: This review summarises developments in the design of formulations in the area of topical drug delivery for treating psoriasis.Keywords
This publication has 100 references indexed in Scilit:
- Granulomatous variant of chronic pigmented purpuric dermatoses: report of four new cases and an association with hyperlipidaemiaClinical and Experimental Dermatology, 2007
- The topical treatment of psoriasisClinical and Experimental Dermatology, 2005
- The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp RegionsJournal of Cutaneous Medicine and Surgery, 2003
- Topical rose Bengal: Pre‐clinical evaluation of pharmacokinetics and safetyLasers in Surgery and Medicine, 2003
- Management of Psoriasis Vulgaris with Methotrexate 0.25% In a Hydrophilic Gel: A Placebo-Controlled, Double-Blind StudyJournal of Cutaneous Medicine and Surgery, 2001
- Response of psoriasis to a new topical retinoid, AGN 190168Journal of the American Academy of Dermatology, 1994
- Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?Journal of the American Academy of Dermatology, 1993
- A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1 betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasisJournal of the American Academy of Dermatology, 1991
- A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasisJournal of the American Academy of Dermatology, 1991
- A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasisJournal of the American Academy of Dermatology, 1991